Management of Hidradenitis Suppurativa in Patients with Metabolic Comorbidities
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Hidradenitis suppurativa is a chronic inflammatory skin condition associated with an increased prevalence of individual metabolic conditions such as insulin resistance, obesity, hyperlipidemia, hypertension, and with the metabolic syndrome, as a constellation of these risk factors. This places affected patients at an increased risk of early cardiovascular morbidity and mortality. Moreover, many of the therapeutic options, including the newer biologics, used in the treatment of hidradenitis suppurativa have both beneficial and adverse metabolic effects. Therefore, it is critical for physicians to consider the complex interactions between the disease process and the treatment options in the holistic management of these patients with an intrinsically higher risk of metabolic consequences. Other chronic systemic inflammatory diseases such as psoriasis and rheumatoid arthritis have been studied more extensively with regard to their associations and share an underlying link with the metabolic syndrome; we can draw upon the existing knowledge in our understanding and management of hidradenitis suppurativa.
Abstract
Hidradenitis suppurativa is a chronic inflammatory skin condition associated with an increased prevalence of individual metabolic conditions such as insulin resistance, obesity, hyperlipidemia, hypertension, and with the metabolic syndrome, as a constellation of these risk factors. This places affected patients at an increased risk of early cardiovascular morbidity and mortality. Moreover, many of the therapeutic options, including the newer biologics, used in the treatment of hidradenitis suppurativa have both beneficial and adverse metabolic effects. Therefore, it is critical for physicians to consider the complex interactions between the disease process and the treatment options in the holistic management of these patients with an intrinsically higher risk of metabolic consequences. Other chronic systemic inflammatory diseases such as psoriasis and rheumatoid arthritis have been studied more extensively with regard to their associations and share an underlying link with the metabolic syndrome; we can draw upon the existing knowledge in our understanding and management of hidradenitis suppurativa.
참고문헌 (35)
- Yu CC., "Hidradenitis suppurativa : a disease of follicular epithelium, rather than apocrine glands", Br J Dermatol, 122, pp.763~769 (1990)
- Zouboulis CC., "European S1 guideline for the treatment of hidradenitis suppurativa", acne inversa, 2015, pp.29, 619~644
- Melnik BC., "Potential role of FoxO1 and mTORC1 in the pathogenesis of Western diet-induced acne", Exp Dermatol, 22, pp.311~315 (2013)
- Schlapbach C., "Expression of the IL-23", Th17 pathway in lesions of hidradenitis suppurativa, 2011, pp.65, 790~798
- van der Zee HH., "Elevated levels of tumour necrosis factor(TNF)-α, interleukin(IL)-1β and IL-10 in hidradenitis suppurativa skin : a rationale for targeting TNF-α and IL-1β", Br J Dermatol, 164, pp.1292~1298 (2011)
- Ferraz-Amaro I., "Metabolic syndrome in rheumatoid arthritis", Mediators Inflamm, 2013, pp.710928~ (2013)
- Miller IM., "Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors", J Am Acad Dermatol, 69, pp.1014~1024 (2013)
- Grundy SM, "Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute", American Heart Association conference on scientific issues related to definition, 2004, pp.24, e13~e18
- Gold DA., "The prevalence of metabolic syndrome in patients with hidradenitis suppurativa", J Am Acad Dermatol, 70, pp.699~703 (2014)
- Shalom G., "Hidradenitis suppurativa and metabolic syndrome : a comparative cross-sectional study of 3207 patients", Br J Dermatol, 173, pp.464~470 (2015)
- Miller IM., "Association of metabolic syndrome and hidradenitis suppurativa", JAMA Dermatol, 150, pp.1273~1280 (2014)
- Sabat R., "Increased prevalence of metabolic syndrome in patients with acne inversa", PLoS One, 7, pp.e31810~ (2012)
- Gisondi P., "Management of moderate to severe psoriasis in patients with metabolic comorbidities", Front Med(Lausanne), 2, pp.1~ (2015)
- Apostolakis S., "IL-1 cytokines in cardiovascular disease : diagnostic, prognostic and therapeutic implications", Cardiovasc Hematol Agents Med Chem, 6, pp.150~158 (2008)
- Sartorius K., "Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity", Br J Dermatol, 161, pp.831~839 (2009)
- Rambhatla PV., "A systematic review of treatments for hidradenitis suppurativa", Arch Dermatol, 148, pp.439~446 (2012)
- Boer J., "Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?", Br J Dermatol, 164, pp.170~175 (2011)
- Kraft JN., "Hidradenitis suppurativa in 64 female patients : retrospective study comparing oral antibiotics and antiandrogen therapy", J Cutan Med Surg, 11, pp.125~131 (2007)
- Verdolini R., "Metformin for the treatment of hidradenitis suppurativa : a little help along the way", J Eur Acad Dermatol Venereol, 27, pp.1101~1108 (2013)
- Grant A., "Infliximab therapy for patients with moderate to severe hidradenitis suppurativa : a randomized, double-blind, placebo-controlled crossover trial", J Am Acad Dermatol, 62, pp.205~217 (2010)
- Giamarellos-Bourboulis EJ., "An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa", Br J Dermatol, 158, pp.567~572 (2008)
- Amano M., "A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa", Int J Dermatol, 49, pp.950~955 (2010)
- Leslie KS., "An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa", J Am Acad Dermatol, 70, pp.243~251 (2014)
- Meier CR, "Health risks of oral contraceptives", Ther Umsch, 68, pp.345~352 (2011)
- Kalender A., "Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner", Cell Metab, 11, pp.390~401 (2010)
- Brauchli YB., "Association between use of thiazolidinediones or other oral antidiabetics and psoriasis : A population based case-control study", J Am Acad Dermatol, 58, pp.421~429 (2008)
- Kim SC., "Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases : a population-based cohort study", Ann Rheum Dis, 74, pp.1968~1975 (2015)
- Sattar N., "Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis : a double-blind, placebo-controlled study", Arthritis Rheum, 56, pp.831~839 (2007)
- Solomon DH., "Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis", JAMA, 305, pp.2525~2531 (2011)
- Lestre S., "Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis : a retrospective cohort study", Eur J Dermatol, 21, pp.916~920 (2011)
- Gisondi P., "Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis : a retrospective cohort study", J Eur Acad Dermatol Venereol, 22, pp.341~344 (2008)
- J. Boer, "Resolution of hidradenitis suppurativa after weight loss by dietary measures, especially on frictional locations", Journal of the European Academy of Dermatology and Venereology, 30(5), pp.895~896 (2016), Wiley-Blackwell[DOI]
- Thomas CL., "Rapid resolution of hidradenitis suppurativa after bariatric surgical intervention", Clin Exp Dermatol, 39, pp.315~317 (2014)
- Kromann CB., "The influence of body weight on the prevalence and severity of hidradenitis suppurativa", Acta Derm Venereol, 94, pp.553~557 (2014)
- Sun K., "Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies", PLoS One, 7, pp.e47791~ (2012)